

Mission Statement

ImageAiD is a company that was created to address the growing gap between available AI technology and medical diagnostic solutions. We strive to advance the way we use information to empower patients with accessible and accurate healthcare solutions.

Background

Peripheral artery disease (PAD) is defined as the narrowing or blockage of arteries, both of which are often caused by athersoschlerosis. Over **100m americans are at risk of developing** PAD due largely to an increase in obesity prevalence, and there are no outstanding treatment methods for treating PAD. Because it's symptoms are often masked by other comorbidities, many patients are not diagnosed until the disease is highly progressed. Thus, the early detection and prevention of PAD is critical to avoiding adverse outcomes such as major adverse cardiac events (MACE), major adverse limb events (MALE), or death. Furthermore, the process of diagnosing and managing PAD is lengthy and expensive. The time between symptom onset and treatment plan is oftentimes upwards of four weeks.

Patient Symptoms Patient complains about symptoms or physician notices risk. A vascular lab test is then requested

Vascular Lab Test Ankle-brachial pressure index (ABPI) is measured by Doppler probe in non-standardised fashion



Treatment Plan Severity and location of the disease can be measured by follow up tests and deeper waveform analysis

Vascular Consult Patient is diagnosed by a vascular specialist who can interpret both the ABPI and waveform morphology

PAD can be diagnosed by classifying doppler waveforms as monophasic, biphasic, or triphasic (see below). Triphasic waveforms indicate healthy arteries with elasticity, whereas monophasic waveforms indicate heavily calcified arteries. Monophasic waveforms are usually indicative of severe PAD onset and can sometimes point towards MACE, MALE, or death.





Novelty and Market Opportunity

Mayo Clinic's tate-of-the-A Dopplei Waveforn Algorithn



1.7B

Global Market Size











Artificial Intelligence Enabled Pocket Doppler Ultrasound Josh Hanson, Ethan Hurt, Anvitha Doddipalli, Jess Miron - S.B.H.S.E.

Clinical Mentor: Dr. Robert McBane II, MD - Mayo Clinic Faculty Mentor: Dr. Jitendran Muthuswamy, PhD - S.B.H.S.E. Technical Mentor: Michael D'Saachs - S.B.H.S.E.

Product Design













Initial Technical Modeling





Fig. 1: Attenutation is directly proportional to both skin depth and attenuation coefficient, both of which typically increase with obesity factors.

Product Needs and Specifications

Current Issues

Diagnostic process is weeks long & requires multiple appointments Inconvenient. Time Consuming. Expensive

Cannot be administered routinely for monitoring / preventative use

Ultrasound gel requires lot of prep & cleanup, adds discomfort to patients

Requires trained vascular technicians

Emitted Frequency	8MHz D
Battery Capacity	450 mAł
Attenuation	Less than 10
Algorithm Accuracy	Greater than



doppler shift tend to be very small compared to those of the emitted signal, requiring precise measurement techniques to produce accurate insights.

User Needs



dB in total attenuation

0.95 area under curve

Governing Equations











We would like to offer our gratitude to our clinical mentor, Dr. McBane, our faculty mentor, Dr. Muthuswamy, and our technical mentor, Mr. Michael D'Saachs. Without their support, this project would not be possible.





Shift	$f_D = rac{2 f_0 v \cos(heta)}{c}$
y and Power otion	$ ext{Capacity} = rac{BL \cdot P_{ ext{avg}}}{V_{dd}}$
sion Rate	$DTR = rac{D}{T}$
sion and tion	$A_{ ext{round-trip}} = lpha \cdot f \cdot (2 \cdot d)$

Circuit Model

Acknowledgements